Zydus Lifesciences Ltd (BOM:532321, NSE:ZYDUSLIFE) wholly owned subsidiary, Zynext Ventures USA LLC, acquired a 5.9% stake in US-based immuno-oncology company Agenus Inc, according to a Tuesday filing on the local bourse.
The purchase of 2.13 million shares cost approximately $16 million at $7.50 per share.
Agenus develops next-generation immunotherapies, including Botensilimab and Balstilimab, which are in advanced clinical trials for multiple cancer types. The investment aims to accelerate these programmes and expand their application in earlier treatment stages.
The deal is subject to regulatory approvals, including those under US antitrust and foreign investment laws. Zynext Ventures plans to complete the acquisition within 60 days, with a possible 30-day extension.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.